SCHEMBL13027817

SCHEMBL13027817

COc1ccc(-c2nccc(C(=O)Nc3cnccc3N3CCNCC3)n2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 10/20 0.51
PIM3 Q86V86 3/20 0.51
PIM1 P11309 1/20 0.51
PIM2 Q9P1W9 4/20 0.50
GSK3A P49840 3/20 0.48
GSK3B P49841 3/20 0.48
JAK2 O60674 1/20 0.48
ROCK2 O75116 1/20 0.48
IGF1R P08069 1/20 0.48
MAPK1 P28482 1/20 0.48
AKT1 P31749 1/20 0.48
RPS6KA3 P51812 1/20 0.48
NEK2 P51955 1/20 0.48
STK3 Q13188 1/20 0.48
CAMK4 Q16566 1/20 0.48
TSSK2 Q96PF2 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.48
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13027893 0.91 CHEK1 (0.49) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027865 0.90 CHEK1 (0.51) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027822 0.89 CHEK1 (0.57) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027930 0.88 PIM1 (0.52) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027869 0.88 CHEK1 (0.48) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13028279 0.87 PIM2 (0.48) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13961713 0.87 PIM2 (0.48) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027885 0.87 CHEK1 (0.51) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027832 0.86 PIM1 (0.55) CHEK1PIM3PIM1PIM2GSK3A
SCHEMBL13027878 0.86 PIM1 (0.51) CHEK1PIM3PIM1PIM2GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293747-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-23 US disclosed
US-8293747-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-23 US disclosed
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS Schering Corporation Patent Department, K-6-1; 1990 (US) 2010-11-11 US disclosed
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS Schering Corporation Patent Department, K-6-1; 1990 (US) 2010-11-11 US disclosed
WO-2009014637-A2 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS MTOR, CDK1, MAP3K8 CHEK1 113/4885PIM3 929/4885PIM1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.